Medicines used to treat pain, anxiety, and insomnia are widely prescribed across the UK, with millions of patients relying on them each year. Clear and consistent safety information is central to ensuring these medicines are used appropriately and risks are understood.
The Medicines and Healthcare products Regulatory Agency has announced strengthened dependency and addiction warnings for several commonly prescribed medicines. The changes affect gabapentinoids, benzodiazepines, and z-drugs, and apply to packaging and patient information provided across the UK.
The Medicines and Healthcare products Regulatory Agency has confirmed updated dependency, addiction, and withdrawal warnings for medicines used to treat pain, anxiety, and insomnia. The announcement follows a safety review supported by the Commission on Human Medicines and applies to gabapentinoids, benzodiazepines, and z-drugs.
The updates will be introduced through revised packaging and patient leaflets over a transition period. The measures are intended to improve patient understanding of risks and support safer use in everyday clinical practice.
Introduction
The MHRA announced on 8 January 2026 that it is strengthening warnings on certain prescription medicines following a comprehensive safety review. The update applies to medicines commonly used across primary and secondary care settings.
The changes focus on clearer communication of dependency, addiction, tolerance, and withdrawal risks. Manufacturers will implement the revised information during a defined transition period.
Regulatory announcement and scope
The MHRA confirmed that warnings on packaging and patient information leaflets will be updated for gabapentinoids, benzodiazepines, and z-drugs. These medicines are prescribed for conditions including neuropathic pain, anxiety, and insomnia.
The strengthened wording will include a clear statement that the medicines may cause addiction, dependence, and withdrawal reactions. The update follows advice from the Commission on Human Medicines after reviewing available safety evidence.
- Gabapentinoids
- Benzodiazepines
- Z-drugs
Changes to packaging and patient information
Patient information leaflets will include clearer definitions of dependence and addiction, alongside improved guidance on how to taper and stop treatment safely. The aim is to support informed discussions between patients and healthcare professionals.
Additional safety messages will advise against combining these medicines with opioids or alcohol. Patients will also be reminded not to share prescribed medicines with others.
Medicines and updated safety messages
| Gabapentinoids | Updated warnings on dependence, addiction, and withdrawal risks |
| Benzodiazepines | Clearer guidance on safe use, tapering, and stopping treatment |
| Z-drugs | Revised patient information highlighting addiction and tolerance |
Findings from the safety review
The Commission on Human Medicines concluded that warnings linked to known risks should be strengthened. The review also supported the development of new patient resources to reinforce safety messages.
Continued engagement with healthcare stakeholders was recommended to support professional training. The MHRA will continue monitoring safety data and consider further regulatory action if required.
- Safety review findings
- Patient resource development
Guidance for patients and healthcare professionals
Patients are advised to speak to a healthcare professional if they have questions about their medicines or experience side effects. Stopping treatment without advice may lead to withdrawal symptoms.
Healthcare professionals are encouraged to discuss dependency risks during treatment and review use regularly. Suspected side effects should be reported through the Yellow Card scheme.
Implementation and monitoring
| Implementation | Manufacturers to update packaging and leaflets during a transition period |
| Monitoring | Ongoing safety surveillance by the MHRA |
Stakeholder Comments
Dr Alison Cave, Chief Safety Officer at the MHRA said;
“Addiction and dependency can happen to anyone taking these medicines, even when used as directed. Strengthening warnings will help patients and healthcare professionals better understand the risks and support safer use.”
Something to Ponder
The MHRA’s updated warnings aim to improve awareness of dependency and addiction risks linked to widely used medicines. Clearer information for patients and healthcare professionals is intended to support safer prescribing and use.
The regulator will continue monitoring these medicines and work with manufacturers and stakeholders to ensure safety information remains up to date.
Sources: Medicines and Healthcare products Regulatory Agency, Commission on Human Medicines, and Drug Safety Update.
Prepared by Ivan Alexander Golden, Founder of THX News, an independent news organisation delivering timely insights from global official sources. Combines AI-analysed research with human-edited accuracy and context.
